TGF-β type I receptor inhibitor (TEW-7197) diminishes myeloma progression by multiple immunomodulatory mechanisms in combination with ixazomib

被引：1
|
作者：
Kim, Byung-Gyu
Sergeeva, Olga
Luo, George
Choi, Sung Hee
Lee, Zhenghong
Kim, Seong-Jin
Letterio, John
Malek, Ehsan
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-2647
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2647
引用
收藏
页数：2
相关论文
共 41 条
  • [41] Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent
    Jin, Cheng Hua
    Krishnaiah, Maddeboina
    Sreenu, Domalapally
    Subrahmanyam, Vura B.
    Rao, Kota S.
    Lee, Hwa Jeong
    Park, So-Jung
    Park, Hyun-Ju
    Lee, Kiho
    Sheen, Yhun Yhong
    Kim, Dae-Kee
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (10) : 4213 - 4238
12345